22.1 C
New York
Monday, June 8, 2026

Tag: words

New Transcribe carpet tile, LVT collection from Tarkett inspires human connectivity, expression

SOLON, Ohio, June 8, 2026 /PRNewswire/ -- From ancient etchings to contemporary icons, human beings have always had an enduring instinct to communicate through...

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

Ormat Technologies Accelerates Enhanced Geothermal System (EGS) Deployments and Introduces Ormega100 Unit to Commercialize and Scale the Largest Binary Unit in the Industry

RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company and the only vertically integrated designer, builder, owner, and operator of geothermal facilities in the world, today announced the Ormega100, a revolutionary new surface power generation unit engineered to deliver higher output than any other binary solution currently on the market. The Ormega100 marks an accelerated opportunity to commercialize and scale its Enhanced Geothermal System (EGS) developments, connecting subsurface development with surface power generation at an accelerated pace.

Consolidated Water Appoints Water Industry Veteran Sachin Chawla as Senior Vice President, Strategy and Growth

GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water treatment plants, has appointed Sachin Chawla to the new position of senior vice president, strategy and growth.

He will direct and manage the company’s business development, sales and marketing activities, while helping the CEO advance M&A and broader business growth initiatives in support of the company’s strategic growth plan.

EPAM and TGS Announce Strategic Collaboration to Accelerate AI Adoption at Scale in Energy Sector

Energy companies gain faster decision making and competitive advantage through integrated, barrier-free workflowsNEWTOWN, Pa., June 8, 2026 /PRNewswire/ -- EPAM Systems, Inc. (NYSE: EPAM), a leading...

Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will be accessible by Zoom webinar (the “Webinar”). The in-person meeting will be held on Thursday, June 18, 2026 at Perkins Place Office Building, located at 525 Portland Street, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.

AmpliTech Group Participates in O-RAN ALLIANCE Global PlugFest Spring 2026 as the Only 64T64R Massive MIMO Radio Vendor, Advancing Multi-Vendor Integration and AI-RAN Development

AmpliTech Group Participates in O-RAN ALLIANCE Global PlugFest Spring 2026 as the Only 64T64R Massive MIMO Radio Vendor

AUTOCANADA EXPANDS COLLISION PLATFORM WITH ACQUISITION OF CONTEMPORARY COACHWORKS IN CALGARY

Acquisition strengthens AutoCanada's position in luxury collision repair, expands its Calgary presence and enhances opportunities for growth and operational synergies.Transaction Highlights Establishes AutoCanada's first luxury collision repair platform in...

Rubicon Organics to Present at Planet MicroCap Las Vegas Powered by MicroCapClub

VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce its participation in Planet MicroCap Las Vegas 2026 Powered by MicroCapClub, taking place June 16-18, 2026, at the Bellagio Resort & Hotel in Las Vegas, Nevada.

Helius Minerals Provides Status Update on Serra Pelada Project Acquisition Transaction

VANCOUVER, BC, June 8, 2026 /CNW/ - Helius Minerals Limited ("Helius" or the "Company") (TSXV: HHH) is pleased to provide an update on the status...

LUCA PROVIDES OPERATIONS AND CORPORATE UPDATE

VANCOUVER, BC, June 8, 2026 /PRNewswire/ - Luca Mining Corp. ("Luca" or the "Company") (TSXV: LUCA) (OTCQX: LUCMF) (Frankfurt: Z68) is pleased to provide an...

Einride and Scan Sverige Partner to Electrify Refrigerated Freight

The addition of Scan Sverige to Einride's growing portfolio of customers highlights the rising demand for scalable, fossil-free freight solutions in high-volume supply chains...

Solidion Technology Granted 7 New Patents on Composite Anode Materials For Batteries Targeting Humanoid Robots, Space-Based Artificial Intelligence Data Centers and the Lunar Economy

 The newly granted patents further strengthen an already globally leading portfolio of patents on anode materials for high-energy and fast-charging lithium batteriesDALLAS, June 8,...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsWords